Molecular Partners AG stock is down -11.4% since 30 days ago. The next earnings date is Mar 14, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a red month, as 0% of the previous 2 February’s closed higher than January.
Molecular Partners AG focuses on the discovery, development, and commercialization of therapeutic proteins. Its products candidates include Abicipar, a DARPin therapeutic candidate, which is in Phase III clinical trials for the treatment of neovascular wet age-related macular degeneration, as well as for diabetic macular edema. MP0420 is a multi-specific DARPin therapy candidate for the SARS-CoV-2 virus. The company also develops MP0423 for treating COVID-19; MP0533, a CD3 T cell candidate for acute myeloid leukemia.
Unlock Exclusive Market Insights! Receive timely updates on market developments. Sign up & stay informed!